Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00303797
Show Display Options
Rank Status Study
1 Completed Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Conditions: Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Multiple Myeloma;   Stage IV Chronic Lymphocytic Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;   Drug: sorafenib tosylate

Indicates status has not been verified in more than two years